111 related articles for article (PubMed ID: 15765111)
1. rHuEpo before high-dose therapy allows autologous peripheral stem-cell transplantation without red blood cell transfusion: a pilot study.
Hunault-Berger M; Tanguy-Schmidt A; Rachieru P; Lévy V; Truchan-Graczyk M; Francois S; Gardembas-Pain M; Dib M; Foussard C; Piard N; Godon A; Solal-Celigny P; Ifrah N
Bone Marrow Transplant; 2005 May; 35(9):903-7. PubMed ID: 15765111
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human erythropoietin therapy after allogeneic hematopoietic cell transplantation with a nonmyeloablative conditioning regimen: low donor chimerism predicts for poor response.
Vanstraelen G; Baron F; Willems E; Bonnet C; Hafraoui K; Frère P; Fillet G; Beguin Y
Exp Hematol; 2006 Jul; 34(7):841-50. PubMed ID: 16797411
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
Baron F; Frère P; Fillet G; Beguin Y
Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of recombinant human erythropoietin in critically ill patients admitted to a long-term acute care facility: a randomized, double-blind, placebo-controlled trial.
Silver M; Corwin MJ; Bazan A; Gettinger A; Enny C; Corwin HL
Crit Care Med; 2006 Sep; 34(9):2310-6. PubMed ID: 16878035
[TBL] [Abstract][Full Text] [Related]
5. Tandem high-dose therapy (HDT) for multiple myeloma: recombinant human erythropoietin therapy given between first and second HDT allows second peripheral blood stem cell transplantation without red blood cell transfusion.
Baron F; Frère P; Fillet G; Beguin Y
Br J Haematol; 2003 Oct; 123(1):103-5. PubMed ID: 14510949
[TBL] [Abstract][Full Text] [Related]
6. Early administration of recombinant erythropoietin improves hemoglobin recovery after reduced intensity conditioned allogeneic stem cell transplantation.
Ivanov V; Faucher C; Mohty M; Bilger K; Ladaique P; Sainty D; Arnoulet C; Chabannon C; Vey N; Camerlo J; Bouabdallah R; Viens P; Maraninchi D; Bardou VJ; Esterni B; Blaise D
Bone Marrow Transplant; 2005 Nov; 36(10):901-6. PubMed ID: 16151421
[TBL] [Abstract][Full Text] [Related]
7. Use of recombinant human erythropoietin after bone marrow transplantation in pediatric patients with acute leukemia: effect on erythroid repopulation in autologous versus allogeneic transplants.
Locatelli F; Zecca M; Pedrazzoli P; Prete L; Quaglini S; Comoli P; De Stefano P; Beguin Y; Robustelli della Cuna G; Severi F
Bone Marrow Transplant; 1994 Apr; 13(4):403-10. PubMed ID: 8019464
[TBL] [Abstract][Full Text] [Related]
8. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients.
Martino M; Oliva E; Console G; Stelitano C; Fujo M; Messina G; Irrera G; Pucci G; Mandaglio R; Callea V; Nobile F; Iacopino P; Morabito F
Support Care Cancer; 2005 Mar; 13(3):182-7. PubMed ID: 15480819
[TBL] [Abstract][Full Text] [Related]
9. Increased iron absorption during autologous blood donation supported by recombinant human erythropoietin therapy.
Bovy C; Baudoux E; Salmon JP; Beguin Y
Transfusion; 2006 Sep; 46(9):1616-23. PubMed ID: 16965592
[TBL] [Abstract][Full Text] [Related]
10. Autologous stem cell transplantation in lymphoma.
Schmitz N; Buske C; Gisselbrecht C
Semin Hematol; 2007 Oct; 44(4):234-45. PubMed ID: 17961722
[TBL] [Abstract][Full Text] [Related]
11. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe.
Fermand JP; Katsahian S; Divine M; Leblond V; Dreyfus F; Macro M; Arnulf B; Royer B; Mariette X; Pertuiset E; Belanger C; Janvier M; Chevret S; Brouet JC; Ravaud P;
J Clin Oncol; 2005 Dec; 23(36):9227-33. PubMed ID: 16275936
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317].
Georgopoulos D; Matamis D; Routsi C; Michalopoulos A; Maggina N; Dimopoulos G; Zakynthinos E; Nakos G; Thomopoulos G; Mandragos K; Maniatis A;
Crit Care; 2005 Oct; 9(5):R508-15. PubMed ID: 16277712
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin beta therapy: an effective strategy to reduce transfusion requirement in children receiving anticancer treatment.
Corapcioglu F; Aksu G; Basar EZ; Demirel A; Oncel S; Mutlu A
Pediatr Hematol Oncol; 2008 Sep; 25(6):509-21. PubMed ID: 18728970
[TBL] [Abstract][Full Text] [Related]
14. Use of exogenous erythropoietin in critically ill patients.
MacLaren R; Gasper J; Jung R; Vandivier RW
J Clin Pharm Ther; 2004 Jun; 29(3):195-208. PubMed ID: 15153081
[TBL] [Abstract][Full Text] [Related]
15. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
16. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
17. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients.
Carreras E; Rosiñol L; Terol MJ; Alegre A; de Arriba F; García-Laraña J; Bello JL; García R; León A; Martínez R; Peñarrubia MJ; Poderós C; Ribas P; Ribera JM; San Miguel J; Bladé J; Lahuerta JJ;
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1448-54. PubMed ID: 18022574
[TBL] [Abstract][Full Text] [Related]
18. High-dose chemotherapy and autologous stem cell transplantation for peripheral T-cell lymphoma: complete response at transplant predicts survival.
Kim MK; Kim S; Lee SS; Sym SJ; Lee DH; Jang S; Park CJ; Chi HS; Huh J; Suh C
Ann Hematol; 2007 Jun; 86(6):435-42. PubMed ID: 17256144
[TBL] [Abstract][Full Text] [Related]
19. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma.
Illerhaus G; Marks R; Ihorst G; Guttenberger R; Ostertag C; Derigs G; Frickhofen N; Feuerhake F; Volk B; Finke J
J Clin Oncol; 2006 Aug; 24(24):3865-70. PubMed ID: 16864853
[TBL] [Abstract][Full Text] [Related]
20. Reduced hemoglobin on day of peripheral blood progenitor cell collection is associated with low graft content of vascular progenitors and increased toxicity after autologous hematopoietic stem cell transplantation.
Kasbia G; Al-Gahtani F; Tay J; Labonté L; Tinmouth A; Ramsay T; Gillingham A; Yang L; Halpenny M; Giulivi A; McDiarmid S; Huebsch L; Allan DS
Transfusion; 2008 Nov; 48(11):2421-8. PubMed ID: 18673346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
